Division of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Expert Rev Respir Med. 2024 Sep;18(9):693-707. doi: 10.1080/17476348.2024.2396413. Epub 2024 Aug 29.
Patients with chronic obstructive pulmonary disease (COPD) are frequently colonized and infected by respiratory pathogens. Identifying these infectious etiologies is critical for understanding the microbial dynamics of COPD and for the appropriate use of antimicrobials during exacerbations.
Traditional methods, such as bacterial and viral cultures, have been standard in diagnosing respiratory infections. However, these methods have significant limitations, including lack of sensitivity and prolonged turnaround time. Modern molecular approaches offer rapid, sensitive, and specific detection, though they also come with their own challenges. This review explores and evaluates the clinical utility of the latest advancements in detecting bacterial and viral respiratory infections in COPD, encompassing molecular techniques, biomarkers, and emerging technologies.
In the evolving landscape of COPD management, integrating molecular diagnostics and emerging technologies holds great promise. The enhanced sensitivity of molecular techniques has significantly advanced our understanding of the role of microbes in COPD. However, many of these technologies have primarily been developed for pneumonia diagnosis or research applications, and their clinical utility in managing COPD requires further evaluation.
慢性阻塞性肺疾病(COPD)患者经常被呼吸道病原体定植和感染。确定这些感染病因对于了解 COPD 的微生物动态以及在加重期适当使用抗生素至关重要。
传统方法,如细菌和病毒培养,一直是诊断呼吸道感染的标准方法。然而,这些方法存在明显的局限性,包括敏感性差和周转时间长。现代分子方法提供了快速、敏感和特异性检测,但它们也有自己的挑战。本综述探讨并评估了检测 COPD 中细菌和病毒呼吸道感染的最新进展在临床应用中的价值,包括分子技术、生物标志物和新兴技术。
在 COPD 管理的不断发展的领域中,整合分子诊断和新兴技术具有巨大的潜力。分子技术的高灵敏度极大地提高了我们对微生物在 COPD 中的作用的理解。然而,这些技术中的许多主要是为肺炎诊断或研究应用而开发的,其在管理 COPD 方面的临床应用需要进一步评估。